Pharma focused digital comms agency ramarketing secures funding for US office

By Gareth Macdonald

- Last updated on GMT

Gettyimages/cbies
Gettyimages/cbies

Related tags Marketing European union

CMO PR agency ramarketing has secured investment to set up a US base in a bid to attract North American contractors interested in accessing the complex European market.

The UK-based firm announced its intention to establish a US operation this week, explaining it has secured a six-figure investment from Fiona Cruickshank, founder of Northumberland manufacturer The Specials Laboratory.

ramarketing – which counts Recipharm and Eurofins as well as specialists like Symbiosis and Juniper among its clients – is looking for sites in pharma and biotech hubs on the East coast.

CEO Raman Sehgal told us helping US contractors win business in Europe and vice-verse is core to the firm's plan.

The US market is certainly competitive but we feel we have the edge over many others due to our knowledge of the European market, which is ideal for companies looking to expand presence in Europe. Likewise, we are already running PR, digital and lead generation campaigns in the US for our European-based clients so having boots on the ground will bring huge added value."

ramarketing's digital-focused approach to marketing is ideal for clients seeking to modernize their communication strategies according to Sehgal.

There are many contract API producers and formulators that are missing commercial opportunities by not having their house in order when it comes to their marketing efforts​.”

Sehgal said having an outdated online presence, limited trade profile or over reliance on traditional sales techniques are common errors, adding that “the contract service companies that are able to get their outbound and inbound strategies working in harmony are the ones that tend to thrive​.”

For many CDMOs/CMOs, it also comes down to a lack of investment into marketing or simply a fear of cost. Getting your marketing efforts working properly does not need to cost the earth and the returns tend to outweigh the outlay​” he said.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Webinars

Headlines